158401-52-6

Usage

Uses

Used in Pharmaceutical Industry:
Cyclophosphamide Related Compound B (25 mg) (3-(2-chloroethyl)-2-oxo-2-hydroxy-1,3,6,2-oxadiazaphosphonane) is used as a metabolite for Cyclophosphamide (C988580), which is an essential chemotherapeutic agent. It plays a crucial role in the treatment of various types of cancer due to its ability to interfere with the growth and spread of cancer cells.
Used in Cancer Treatment:
Cyclophosphamide Related Compound B (25 mg) (3-(2-chloroethyl)-2-oxo-2-hydroxy-1,3,6,2-oxadiazaphosphonane) is used as an active metabolite in cancer treatment for its cytotoxic properties. It is involved in the process of breaking down the parent drug, Cyclophosphamide, into its active form, which can then target and destroy cancer cells effectively.
Used in Research and Development:
In the field of research and development, Cyclophosphamide Related Compound B (25 mg) (3-(2-chloroethyl)-2-oxo-2-hydroxy-1,3,6,2-oxadiazaphosphonane) is used as a key compound for studying the mechanisms of action, metabolism, and potential side effects of Cyclophosphamide. This helps in the development of new and improved cancer treatments and understanding the drug's interactions with various biological systems.
Used in Quality Control and Analysis:
Cyclophosphamide Related Compound B (25 mg) (3-(2-chloroethyl)-2-oxo-2-hydroxy-1,3,6,2-oxadiazaphosphonane) is also used in the quality control and analysis of Cyclophosphamide drug products. It serves as a reference material for assessing the purity, potency, and stability of the drug, ensuring that the final product meets the required standards for safety and efficacy.

InChI:InChI=1/C7H16ClN2O3P/c8-2-5-10-6-4-9-3-1-7-13-14(10,11)12/h9H,1-7H2,(H,11,12)

Upstream product

• 64724-10-3 1-(2-chloro-ethyl)-tetrahydro-[1,3,2]diazaphospholo[2,1-b][1,3,2]oxazaphosphinine (S)-9-oxide 
• 50-18-0 cyclophosphamide 

Relevant academic research and scientific papers

Chemical and biological evaluation of hydrolysis products of cyclophosphamide

31P NMR spectroscopy was used to study the products of the decomposition of cyclophosphamide (1) in buffered solutions at pH's ranging between 1.2 and 8.6 at 20 °C and at pH 7.4 at 37 °C. At pH 1.2, 1 undergoes a rapid breakdown (t( 1/2 ) = 1.4 days) of the two P-N bonds, giving compounds 2 [HN(CH2CH2Cl)2] and 3 [H2N(CH2)3OP(O)(OH)2] as hydrochlorides. No intermediates were detected. At pH's between 5.4 and 8.6, hydrolysis of 1 during 17 days leads to the sole and previously unknown nine-membered ring compound 13. 13 results from the intramolecular alkylation of 1 giving the bicyclic compound 7 followed by the exothermal hydrolytic breakdown of the P- N bond of its six-membered ring. At pH 2.2 and 3.4, the two hydrolytic pathways coexist since, beside compounds 2 and 3, the hydrochloride of compound 9 [Cl(CH2)2NH(CH2)2NH(CH2)3OP(O)(OH)2] is formed, resulting from the acid-catalyzed breakdown of the P-N bond in the nine-membered ring compound 13. At pH 2.2, the presence of chloride ion affected neither the stability of 1 nor the contribution of the two competing hydrolytic pathways. At pH's ranging from 3.4 to 8.6, there is little degradation of 1 since more than 95% of initial 1 was still present after 7 days at 20 °C. Under physiological conditions (pH 7.4, 37 °C) after 6 days, 45% of 1 is hydrolyzed (t( 1/2 ) = 6.6 days), leading essentially (30% of initial 1) to the nine-membered ring compound 13. The rate of hydrolysis of 13 and the nature of its hydrolysis products were found to depend on pH over the range 0-8.6. After a single ip injection to mice, compounds 3, 9, and 13 were less toxic than 1. They did not exhibit any direct cytotoxic efficacy on the colony- forming capacity of L1210 cells in vitro, and they had no antitumor activity in vivo against P388 leukemia.